Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis

Conclusions: We suggest that NIL could be a biomarker of therapeutic efficacy in patients with RRMS treated with natalizumab, and that the risk of relapse may be higher in patients with a lower-than-expected NIL.

http://msj.sagepub.com/cgi/content/abstract/22/7/921?rss=1

Source: Multiple Sclerosis - June 1, 2016 Category: Neurology Authors: Signoriello, E., Lanzillo, R., Brescia Morra, V., Di Iorio, G., Fratta, M., Carotenuto, A., Lus, G. Tags: Original Research Papers Source Type: research